Outcomes
tumor, Tumor, TRAEs, Cancer
DISEASE PROGRESSION, TUMOR, ADVERSE EVENT, TUMOR, ADVERSE EVENTS, DISEASE, SECONDARY, CANCER
The primary endpoint was the objective response rate (ORR) of the target lesions. Radiographic tumor response evaluation was performed using CT obtained after camrelizumab every 2 cycles until disease progression or unacceptable toxic effects. Tumor response was determined based on RECIST 1.1.The secondary endpoints included disease control rate (DCR) of target lesions, treatment-related adverse events (TRAEs), and clinical benefit rate (CBR). TRAEs and serious adverse events (SAEs) were collected and evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0.3).